Adrienne C Scheck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8855001/publications.pdf

Version: 2024-02-01

52 papers	1,439 citations	516561 16 h-index	454834 30 g-index
54 all docs	54 docs citations	54 times ranked	2098 citing authors

#	Article	IF	Citations
1	Molecular Imaging of Glucose Metabolism for Intraoperative Fluorescence Guidance During Glioma Surgery. Molecular Imaging and Biology, 2021, 23, 586-596.	1.3	4
2	Progress in Confocal Laser Endomicroscopy for Neurosurgery and Technical Nuances for Brain Tumor Imaging With Fluorescein. Frontiers in Oncology, 2019, 9, 554.	1.3	28
3	The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemotherapy and radiotherapy. Neuro-Oncology, 2019, 21, iv8-iv8.	0.6	6
4	Scanning Fiber Endoscope Improves Detection of 5-Aminolevulinic Acidâ€"Induced Protoporphyrin IX Fluorescence at the Boundary of Infiltrative Glioma. World Neurosurgery, 2018, 113, e51-e69.	0.7	50
5	The ketogenic diet for patients with brain tumours: Two parallel randomised trials. Neuro-Oncology, 2018, 20, i7-i8.	0.6	0
6	Probe-based three-dimensional confocal laser endomicroscopy of brain tumors: technical note. Cancer Management and Research, 2018, Volume 10, 3109-3123.	0.9	27
7	Chemotherapy Resistance. , 2018, , 87-104.		0
8	Mathematical Analysis of Glioma Growth in a Murine Model. Scientific Reports, 2017, 7, 2508.	1.6	37
9	Improving the utility of 1H-MRS for the differentiation of glioma recurrence from radiation necrosis. Journal of Neuro-Oncology, 2017, 133, 97-105.	1.4	21
10	OP16. THE KETOGENIC DIET INDUCES EPIGENETIC CHANGES THAT PLAY KEY ROLES IN TUMOUR DEVELOPMENT. Neuro-Oncology, 2017, 19, i28-i28.	0.6	5
11	GENE-21. THE KETOGENIC DIET ALTERS THE EPIGENETIC LANDSCAPE OF GBM TO POTENTIATE THE EFFECTS OF CHEMO AND RADIOTHERAPY. Neuro-Oncology, 2017, 19, vi96-vi97.	0.6	0
12	ACTR-15. THERAPEUTIC KETOGENIC DIET (KD) WITH RADIATION AND CHEMOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA â€" PRELIMINARY RESULTS FROM NCT02046187. Neuro-Oncology, 2017, 19, vi4-vi4.	0.6	4
13	EXTH-48. THE KETONE BODY Î²-HYDROXYBUTYRATE CHEMO- AND RADIO-SENSITIZES MALIGNANT GLIOMA CELLS BY INHIBITING HISTONE DEACETYLASE ACTIVITY AND DOWNREGULATING EXPRESSION OF RAD51. Neuro-Oncology, 2017, 19, vi83-vi83.	0.6	0
14	Abstract 1125A: Î²-hydroxybutyrate inhibits histone deacetylase activity and radiosensitizes malignant glioma cells. Cancer Research, 2017, 77, 1125A-1125A.	0.4	2
15	Tumor Metabolism, the Ketogenic Diet and Î²-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy. Frontiers in Molecular Neuroscience, 2016, 9, 122.	1.4	95
16	EXTH-16. THE KETONE BODY Î²-HYDROXYBUTYRATE INHIBITS HISTONE DEACETYLASE ACTIVITY AND ALTERS EXPRESSION OF DNA REPAIR PROTEINS IN MALIGNANT GLIOMA CELLS. Neuro-Oncology, 2016, 18, vi62-vi63.	0.6	0
17	Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer, 2016, 16, 310.	1.1	111
18	The Ketogenic Diet as an Adjuvant Therapy for Brain Tumors and Other Cancers. , 2016, , 89-109.		1

#	Article	IF	Citations
19	Abstract 1022: The ketone body Î²-hydroxybutyrate down regulates c-Myc signaling in a malignant glioma model. , 2016, , .		0
20	Ketogenic Diet as Adjunctive Therapy for Malignant Brain Cancer. , 2016, , .		0
21	The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model. PLoS ONE, 2015, 10, e0130357.	1.1	94
22	ATPS-77THE KETONE BODY ÃŸ-HYDROXYBUTYRATE RADIOSENSITIZES GLIOBLASTOMA MULTIFORME STEM CELLS. Neuro-Oncology, 2015, 17, v35.2-v35.	0.6	1
23	The Ketogenic Diet for the Adjuvant Treatment of Malignant Brain Tumors. , 2015, , 125-135.		1
24	The ketogenic diet for the treatment of malignant glioma. Journal of Lipid Research, 2015, 56, 5-10.	2.0	74
25	Abstract 240: The ketogenic diet alters the expression of microRNAs that play key roles in tumor development. , 2015, , .		2
26	Abstract 3346: The ketone body Î²-hydroxybutyrate increases radiosensitivity in glioma cell lines in vitro. , 2015, , .		6
27	Abstract CT213: Clinical effects of a ketogenic diet on brain tumor patients: tumor growth and quality of life. , 2015, , .		1
28	Abstract 1344: The ketogenic diet enhances immunity in a mouse model of malignant glioma. , 2015, , .		0
29	Abstract B73: Ketogenic diet enhances immunity to glioblastoma. , 2015, , .		0
30	Monocyte-Derived Cells of the Brain and Malignant Gliomas: The Double Face of Janus. World Neurosurgery, 2014, 82, 1171-1186.	0.7	24
31	Abstract 1440: Metabolic therapy reduces expression of PECAM-1/CD31 and decreases peritumoral edema in a mouse model of malignant glioma. , 2014, , .		0
32	Abstract 4441: The ketogenic diet potentiates radiation therapy in a mouse model of glioma: effects on inflammatory pathways and reactive oxygen species.. Cancer Research, 2013, 73, 4441-4441.	0.4	6
33	The ketogenic diet for the treatment of glioma: Insights from genetic profiling. Epilepsy Research, 2012, 100, 327-337.	0.8	43
34	Abstract 3217: Mechanistic analysis of the ketogenic diet versus KetoCalÂ® as adjuvant treatments for malignant glioma. Cancer Research, 2012, 72, 3217-3217.	0.4	6
35	The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma. PLoS ONE, 2012, 7, e36197.	1.1	221
36	Abstract 624: Efficacy of KetoCal as an adjuvant therapy for malignant gliomas. , 2011, , .		0

#	Article	IF	Citations
37	Use of Indocyanine Green Near-Infrared Laser Confocal Endomicroscopy In Vivo. Neurosurgery, 2010, 67, 562.	0.6	1
38	The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutrition and Metabolism, 2010, 7, 74.	1.3	166
39	Abstract 638: Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. Cancer Research, 2010, 70, 638-638.	0.4	5
40	Abstract 1789: NFKBIA deletion in malignant gliomas. , 2010, , .		0
41	The central nervous system at the core of the regulation of energy homeostasis. Frontiers in Bioscience - Elite, 2009, 1, 448.	0.9	3
42	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Medical Genomics, 2008, 1, 52.	0.7	181
43	Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. Journal of Neurosurgery, 2008, 109, 106-117.	0.9	37
44	Chemotherapy Resistance. , 2006, , 89-104.		1
45	Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. BMC Cancer, 2006, 6, 2.	1.1	5
46	Tumor Necrosis Factor-Î±â€"Induced Protein 3 As a Putative Regulator of Nuclear Factor-ÎºBâ€"Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas. Journal of Clinical Oncology, 2006, 24, 274-287.	0.8	127
47	Identification of transforming growth factor-?1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display. Cancer, 2000, 89, 850-862.	2.0	8
48	BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes. Genes Chromosomes and Cancer, 1993, 8, 137-148.	1.5	15
49	Tumor Heterogeneity and Intrinsically Chemoresistant Subpopulations in Freshly Resected Human Malignant Gliomas. , 1991, 57, 243-262.		11
50	Molecular Biological Events in the Selection of Chemotherapy Resistant-Cells in Human Malignant Gliomas. , 1991, , 21-26.		2
51	A tool for reproducible research: From data analysis (in R) to a typeset laboratory notebook (as .pdf) using the text editor Emacs with the 'mp' package. F1000Research, 0, 4, 483.	0.8	2
52	Towards reproducible research: From data analysis (in R) to a typeset laboratory notebook (as .pdf) using the text editor Emacs with the 'mp' package. F1000Research, 0, 4, 483.	0.8	2